Risk-sharing agreements are growing at a rate of 24%
Pharmaceutical Technology
FEBRUARY 10, 2023
This is not the first treatment to come with a high price tag. Notably, 2022 saw the greatest number of RSA deals arranged, surpassing the previous record in 2017, when the first gene therapy, Novartis’s Kymriah (tisagenlecleucel), was approved and priced at $475,000.
Let's personalize your content